Back

Can-Fite reports longer blinded survival in liver cancer trial, secures $4 million

Verifying
  • Can-Fite BioPharma reported longer blinded survival in its Phase 3 liver cancer trial.
  • $4 million in gross proceeds is targeted through the repriced warrant exercise.
  • CANF shares were down 22.49% at $2.55 on Wednesday, Benzinga Pro data showed.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.